Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone-induced atopic dermatitis model.

“This study was performed to investigate the effects of CBR agonists on skin inflammation, using acute and chronic inflammation animal models.

All of the results suggest that topical application of CB1R-specific agonist can be beneficial for alleviating the inflammatory symptoms in chronic skin diseases, including atopic dermatitis.”

http://www.ncbi.nlm.nih.gov/pubmed/26095080

Leave a Reply

Your email address will not be published. Required fields are marked *